NEW YORK (GenomeWeb News) – Pressure BioSciences has raised around $1.7 million through a private placement of units, the firm disclosed today in a filing with the US Securities and Exchange Commission.

The company said that it sold 4,257 units at a price of $400 per unit. The $1.7 million it raised is the first tranche of a targeted $2 million, said Pressure Bio, adding that it expects to close one or more tranches on or before Feb. 28, 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.